Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Acta Neurol Belg ; 122(2): 385-390, 2022 Apr.
Article in English | MEDLINE | ID: mdl-33738777

ABSTRACT

Tuberous sclerosis complex (TSC) is an autosomal-dominant, multi-system, neurocutaneous disorder characterized by hamartomas in multiple organs. This study aimed to evaluate the clinical and paraclinical manifestations of children with TSC. The clinical and paraclinical characteristics of 79 children with TSC were evaluated and the possible correlations between the factors were calculated. Among the studied children which composed of 41 females (51.9%) and 38 males (48.1%), skin manifestations as hypopigmented macules as well as the brain involvement as cortical tubers in all (100%) cases, seizure in 74 (93.7%), and sub-ependymal nodules in 73 (92.4%) patients were the most common findings. The renal angiomyolipoma was diagnosed in 36 (70.6%) out of 51 patients. Subependymal giant cell astrocytoma in 25 (3/54%) out of 46 patients, retinal hamartoma in 15 (42.9%) out of 35 patients, and cardiac rhabdomyoma in 17 (41.3%) out of 46 patients were diagnosed. Furthermore, 50 (63.3%) out of 79 patients had psychological disorders that had a significant correlation with the prevalence of seizures (p = 0.002). Given the multi-systemic involvement of TSC, it is necessary that all organs of the patients even without any related clinical symptom or sign be examined regularly for proper therapeutic intervention and prevent disease progression. The growth of hamartomas in the brain and kidneys can be life-threatening; therefore, these organs have more importance to be regularly followed up and examined.


Subject(s)
Angiomyolipoma , Astrocytoma , Hamartoma , Kidney Neoplasms , Tuberous Sclerosis , Astrocytoma/complications , Child , Female , Humans , Male , Seizures , Tuberous Sclerosis/complications
2.
Curr Mol Med ; 21(2): 87-95, 2021.
Article in English | MEDLINE | ID: mdl-32520687

ABSTRACT

Exosomes are nano-sized vesicles secreted by nearly all cells and have received massive attention recently. In addition to their roles in pathophysiological processes and diagnostic evaluations, recently, several studies have applied exosomes to design novel therapeutic applications. Exosomes can be derived from a variety of cells and tissues and based on the source, they can carry different native contents such as DNAs, non-coding small RNAs, mRNAs, and proteins. They can also be engineered by adding desirable agents including specific biomolecules or drugs. Both forms can be therapeutically used for delivering their cargoes to the target cells and desirably alter their functions. The present study aimed to provide a comprehensive review of the various studies which applied exosomes as a therapeutic tool in the treatment of different types of diseases including cancer, cardiovascular, neurologic, psychiatric, liver, and kidney diseases.


Subject(s)
Biomarkers/metabolism , Brain Diseases/therapy , Cardiovascular Diseases/therapy , Exosomes/metabolism , Neoplasms/therapy , Protective Factors , Animals , Brain Diseases/metabolism , Brain Diseases/pathology , Cardiovascular Diseases/metabolism , Cardiovascular Diseases/pathology , Drug Delivery Systems , Humans , Neoplasms/metabolism , Neoplasms/pathology
3.
Acta Neurol Belg ; 121(2): 483-487, 2021 Apr.
Article in English | MEDLINE | ID: mdl-31677042

ABSTRACT

Dietary therapy has an important role in the therapeutic process in children suffering refractory epilepsy. There are two kinds of dietary therapy which are the most common in children with refractory epilepsy: The classic ketogenic diet (KD) and the modified Atkins diet (MAD). The purpose of the present study was to compare the efficacy, tolerability, and compliance of these two dietary therapies in the children who have refractory epilepsy during 6 months of treatment. From March 2017 to November 2018, 45 children aged 2-15 years who had refractory epilepsy were randomly allocated in KD or MAD group. The intervention period was 6 months in both groups. The frequencies of seizures were determined from parental reports and were compared between the groups. The patients with upper than 50% reduction in seizure frequency were deemed as responders to the diets. Twenty-four patients were assigned to the KD and 11 patients to the MAD. Overall, 45.8% of children treated with the KD and 45.5% of children treated with MAD had over than 50% response to the diet therapies. The difference was not statistically significant (P = 0.437). The MAD was more advantageous regarding better tolerability and fewer side effects. There is not much difference regarding the efficacy between the MAD and classic KD. The MAD with fewer side effects may be more suitable as the first line of dietary therapy in children with refractory epilepsy.


Subject(s)
Diet, High-Protein Low-Carbohydrate/methods , Diet, Ketogenic/methods , Drug Resistant Epilepsy/diet therapy , Drug Resistant Epilepsy/diagnosis , Adolescent , Child , Child, Preschool , Diet, High-Protein Low-Carbohydrate/trends , Diet, Ketogenic/trends , Female , Follow-Up Studies , Humans , Male , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...